LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription Program

Core Insights - LifeMD has launched a subscription program for Novo Nordisk's Wegovy® (semaglutide), providing significant annual savings for patients [1][2] - The subscription model enhances patient access to branded GLP-1 therapy and supports treatment adherence [2][3] Company Overview - LifeMD is a leading provider of virtual primary care services, offering telemedicine and access to laboratory and pharmacy services across more than 200 conditions [5] - The company has a vertically integrated digital care platform and a 50-state affiliated medical group [5] Collaboration Details - The Wegovy® subscription program is an extension of LifeMD's collaboration with Novo Nordisk, which has evolved from an initial pharmacy integration to a comprehensive commercial partnership [3] - LifeMD is recognized as a telehealth provider on both the NovoCare® and Wegovy® websites, highlighting the strength of their relationship [3] Patient Benefits - Patients enrolled in the Wegovy® program through LifeMD can save up to $1,200 annually for injectable formulations and $600 for oral therapy [2] - The program offers a comprehensive care experience, including virtual visits, ongoing clinical oversight, diagnostic testing, and simplified billing [4]